Patent offices to revise stem cell guidance post-Brüstle
Patent offices in Europe are considering whether to change their approach to the patenting of stem cell-related inventions following a Court of Justice ruling last month
On October 18 Europe's highest court held that patents covering stem cells derived from human embryos are not permissible under the EU Biotechnology Directive.
In reaching its conclusion in the Brüstle case, the Court defined embryos widely, saying that they...
Please log in
to read the rest of this article. New to Managing Intellectual Property?
Take advantage of free access to up to 5 articles on Managing IP and become a member today. It’s free to join and the benefits start straight away.
Please make sure you log in to read the rest of the article.
Join us nowGain FREE access to up to five free articles when you register now.